International Immunopharmacology, Год журнала: 2021, Номер 101, С. 108255 - 108255
Опубликована: Окт. 16, 2021
Язык: Английский
International Immunopharmacology, Год журнала: 2021, Номер 101, С. 108255 - 108255
Опубликована: Окт. 16, 2021
Язык: Английский
Blood, Год журнала: 2022, Номер 140(3), С. 222 - 235
Опубликована: Янв. 5, 2022
Язык: Английский
Процитировано
98Physiological Reviews, Год журнала: 2020, Номер 101(2), С. 545 - 567
Опубликована: Окт. 30, 2020
Evolving information has identified disease mechanisms and dysregulation of host biology that might be targeted therapeutically in coronavirus 2019 (COVID-19). Thrombosis coagulopathy, associated with pulmonary injury inflammation, are emerging clinical features COVID-19. We present a framework for thrombosis COVID-19 initially derive from interaction SARS-CoV-2 ACE2, resulting angiotensin signaling subsequent inflammation tissue injury. These responses result increased by thrombin (proteinase-activated) purinergic receptors, which promote platelet activation exert pathological effects on other cell types (e.g., endothelial cells, epithelial fibroblasts), further enhancing Inhibitors receptors may, thus, have therapeutic blunting platelet-mediated thromboinflammation dysfunction types. Such inhibitors include agents anti-platelet drugs) approved indications, could repurposed to treat, potentially improve the outcome of, patients. COVID-19, caused virus, drives signaling, which, turn, increases thrombin-mediated purinergic-mediated platelets increase inflammation. This impacts lungs can also systemic effects. drive or coagulation cascade provide opportunities treat thromboinflammation.
Язык: Английский
Процитировано
101BMC Nephrology, Год журнала: 2020, Номер 21(1)
Опубликована: Окт. 27, 2020
Abstract The pandemic of coronavirus disease 2019 (CoVID-19) has been an unprecedented period. afflicts multiple organ systems, with acute kidney injury (AKI) a major complication in seriously ill patients. incidence AKI patients CoVID-19 is variable across numerous international studies, but the high and its associated worse outcomes critical care setting are consistent finding. A multitude patterns mechanisms have elucidated, novel strategies to address shortage renal replacement therapy equipment implemented. also had consequences on longitudinal management chronic end stage disease. Kidney transplant recipients may be especially susceptible as result immunosuppression, preliminary studies demonstrating mortality rates. Increased surveillance low threshold for testing adjustment immunosuppression regimen during periods illness recommended.
Язык: Английский
Процитировано
100Molecular & Cellular Proteomics, Год журнала: 2021, Номер 20, С. 100159 - 100159
Опубликована: Янв. 1, 2021
Язык: Английский
Процитировано
100International Immunopharmacology, Год журнала: 2021, Номер 101, С. 108255 - 108255
Опубликована: Окт. 16, 2021
Язык: Английский
Процитировано
83